VERIFY
VERIFY showed that weekly rusfertide, a hepcidin mimetic, freed most PV patients from phlebotomy and improved their symptoms, leading to the drug's approval in 2026.
Overview
VERIFY randomised 293 patients with PV who needed frequent phlebotomies to weekly subcutaneous rusfertide or placebo on top of their usual treatment. Over weeks 20 to 32, 77 percent on rusfertide were responders (no phlebotomy needed) versus 33 percent on placebo, with fewer phlebotomies, sustained haematocrit control and better patient-reported fatigue and itch; the results were presented at ASCO 2025 and published the same year. The FDA approved rusfertide in 2026.
- 77 vs 33 out of 100 reached this endpoint with Rusfertide compared with Placebo; 44 more per 100.
- Roughly one extra person helped for every 2 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- This endpoint is not one of the standard survival or response measures; read it alongside the trial's primary result.
- These results apply to the people the trial enrolled: Phlebotomy-dependent polycythaemia vera: rusfertide versus placebo added to standard care. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
293 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Clinical response weeks 20 to 32primary | Rusfertide | 147 | 77% | - | - | - |
| Placebo | 146 | 33% |
Similar pages
not linked directly; found by shared links- TrialCYTO-PV
Shares Phlebotomy (venesection), Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tags polycythaemia-vera, mpn.
- TrialLow-PV
Shares Hepcidin-based control as first-line treatment in low-risk polycythaemia vera, Polycythaemia vera (PV) and the tags polycythaemia-vera, mpn.
- TermAquagenic pruritus
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tags polycythaemia-vera, mpn.
- TrialRESPONSE
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tags polycythaemia-vera, mpn.
- TermErythromelalgia
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tags polycythaemia-vera, mpn.
- TermPost-PV myelofibrosis (spent phase)
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tags polycythaemia-vera, mpn.
- TermJAK2 V617F
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tags polycythaemia-vera, mpn.
- TrialPROUD-PV and CONTINUATION-PV
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tags polycythaemia-vera, mpn.